Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39361   clinical trials with a EudraCT protocol, of which   6446   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-005732-18
    Sponsor's Protocol Code Number:DU176b-A-U157
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:
    Date on which this record was first entered in the EudraCT database:2016-06-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2015-005732-18
    A.3Full title of the trial
    A Phase 1, Open-Label, Single-dose, Non-randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients
    Étude en ouvert non randomisée de phase 1, à dose unique, visant à évaluer la pharmacocinétique (PK) et la pharmacodynamie (PD) de l’edoxaban chez l’enfant
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study of an oral anticoagulant (Edoxaban) in children
    Etude d'un anticoagulant oral (edoxaban) chez l'enfant
    A.4.1Sponsor's protocol code numberDU176b-A-U157
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02303431
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/302/2015
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDaiichi Sankyo , Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDaiichi Sankyo Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDaiichi Sankyo, Inc.
    B.5.2Functional name of contact pointClinical Trial Information Contact
    B.5.3 Address:
    B.5.3.1Street Address399 Thornall Street
    B.5.3.2Town/ cityEdison
    B.5.3.3Post codeNJ08837
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1732 5905000
    B.5.5Fax number+1732 9065690
    B.5.6E-maileu_cta@dsi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lixiana (60 mg Film-coated tablet)
    D.2.1.1.2Name of the Marketing Authorisation holderDaiichi Sankyo Europe GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEdoxaban tosylate
    D.3.2Product code DU-176b
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEdoxaban
    D.3.9.1CAS number 480449-70-5
    D.3.9.2Current sponsor codeEdoxaban
    D.3.9.4EV Substance CodeSUB32701
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lixiana
    D.2.1.1.2Name of the Marketing Authorisation holderDaiichi Sankyo Europe GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEdoxaban tosylate
    D.3.2Product code DU-176b
    D.3.4Pharmaceutical form Granules for oral suspension
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEdoxaban
    D.3.9.1CAS number 480449-70-5
    D.3.9.2Current sponsor codeEdoxaban
    D.3.9.4EV Substance CodeSUB32701
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lixiana (30 mg film-coated tablet)
    D.2.1.1.2Name of the Marketing Authorisation holderDaiichi Sankyo Europe GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEdoxaban tosylate
    D.3.2Product code DU-176b
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEdoxaban
    D.3.9.1CAS number 480449-70-5
    D.3.9.2Current sponsor codeEdoxaban
    D.3.9.4EV Substance CodeSUB32701
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number15
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients who are at risk of thromboembolic events (e.g., patients with thrombophilia, congenital heart disease, presence of a central venous catheter);

    Patients with cardiac conditions who may need anticoagulation therapy; or

    Patients with sickle cell disease who may need anticoagulation therapy.
    Patients qui présentent un risque d’épisodes thromboemboliques (par ex. patients souffrant de thrombophilie, d’une maladie cardiaque congénitale, présence d’un cathéter veineux central) ;

    Patients atteints de troubles cardiaques pouvant nécessiter un traitement anticoagulant ; ou

    Patients porteurs de la drépanocytose pouvant nécessiter un traitement anticoagulant.
    E.1.1.1Medical condition in easily understood language
    Edoxaban is being investigated for use in pediatric patients who may require anticoagulation therapy
    L'edoxaban sera étudié chez une population d'enfants qui nécessite un traitement par anti-coagulant
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10010495
    E.1.2Term Congenital heart disease NOS
    E.1.2System Organ Class 100000004850
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10057396
    E.1.2Term Thrombophilia
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To characterize the PK of Edoxaban in pediatric patients following oral single-dose administration.
    Caractériser la pharmacocinétique de l’edoxaban chez l’enfant à la suite de l'administration orale d'une dose unique
    E.2.2Secondary objectives of the trial
    - To evaluate the PD effects of edoxaban in pediatric patients following single-dose oral administration
    - To evaluate the safety and tolerability of single-dose oral administration of edoxaban in pediatric patients
    - To assess metabolite exposure (D21-2393, D21-3231, D21-1402, and D21-2135) in pediatric patients
    - To evaluate the palatability (bitterness, sweetness, and overall taste or aroma) of the liquid oral suspension of edoxaban
    Caractériser les effets de la pharmacodynamie de l’edoxaban chez l’enfant à la suite de l'administration orale d'une dose unique
    Évaluer la sécurité d’emploi et la tolérance d’une dose unique d’edoxaban administrée par voie orale chez l’enfant
    Évaluer l’exposition au métabolite (D21-2393, D21-3231, D21-1402 et D21-2135) chez l’enfant
    Évaluer la palatabilité (amertume, douceur et goût ou arôme global) de la suspension orale liquide d’edoxaban
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Able to provide written informed assents (patients, when applicable) and ICFs (signed by parent/legal guardian) prior to participating in the study
    2. Male or female patients 0 to < 18 years of age on the day of dosing
    3. Patients 2 to < 18 years of age must have a body mass index (BMI) between the 5th and 95th percentile based on the 2000 CDC Growth Charts7 (the maximum number of patients in each dose group that have a BMI between 85th and 95th percentile should not be more than 2 patients). Patients < 2 years of age must have a body weight between the 5th and 90th percentile based on the 2000 CDC Growth Charts7
    4. Female patients who have had menarche must test negative for pregnancy at screening and check-in
    5. Female patients who have had menarche and are sexually active must use an acceptable contraception method for at least 30 days prior to edoxaban dose
    6. Patients/Legal guardian(s) must agree to food and drug restrictions during the study
    7. Patients must agree to abstain from the use of nonsteroidal anti-inflammatory drugs (such as ibuprofen), and antiplatelet and anticoagulant agents (except for low-dose aspirin) from 24 hours prior to edoxaban dose until after the last PK sample is collected
    8. Patients on low-dose aspirin treatment (1 to 5 mg/kg/day, maximum of 100 mg/day) with an interruption of aspirin 24 hours prior to edoxaban dose and resuming 24 hours after edoxaban dose are permitted to participate in the study per the Investigator’s judgment that this does not place the patients at risk
    9. Patients must agree to abstain from CYP3A4 inhibitors/inducers and P-gp inhibitors/inducers for 14 days prior to the edoxaban dose to until after the last PK sample is collected (See Section 5.2)
    10. Patients must agree to abstain from and/or legal guardians must agree not to give the patient cola, tea, coffee, chocolate, and other caffeinated drinks and food from 48 hours before dose administration through check-out (See Section 5.3 for a complete list)
    11. Other than signs and symptoms characteristic to their disease state, patients are to be in good health as determined by the absence of clinically significant deviations from normal, with respect to medical and surgical history, physical examination, vital signs, and laboratory reports, as deemed by the Investigator and the Sponsor, prior to enrollment
    12. Patients must agree to abstain from and/or legal guardians must agree not to give the patient St. John’s Wort and food/supplement and beverages containing grapefruit, grapefruit juice, and Seville oranges from 14 days before the first dose through the end of the study (See Section 5.3)
    1. Être en mesure de fournir des assentiments éclairés écrits (patients, le cas échéant) et des fiches d’information et d’autorisation (signés par le parent/tuteur légal) avant de participer à l’étude

    2. Être un patient de sexe masculin ou féminin âgé de 0 à  18 ans le jour de l’administration du produit

    3. Les patients âgés de 2 à < 18 ans doivent présenter un indice de masse corporelle (IMC) compris entre le 5e et le 95e percentile, sur la base des courbes de croissance du CDC 20007 (dans chaque groupe posologique, 2 patients au maximum peuvent présenter un IMC compris entre le 85e et le 95e percentile). Les patients de < 2 ans doivent présenter une masse corporelle comprise entre le 5e et le 90e percentile, sur la base des courbes de croissance du CDC7

    4. Les patientes de sexe féminin ayant eu leurs premières règles doivent présenter un test de grossesse négatif lors de la sélection et de l’arrivée

    5. Les patientes de sexe féminin ayant eu leurs premières règles et qui sont sexuellement actives doivent utiliser un moyen de contraception acceptable pendant au moins 30 jours avant l’administration de la dose d’edoxaban

    6. Les patients/le ou les tuteurs légaux doivent accepter les restrictions alimentaires et médicamenteuses pendant l’étude

    7. Les patients doivent accepter de s’abstenir d’utiliser des médicaments anti-inflammatoires non stéroïdiens (par ex. ibuprofène) et des agents antiplaquettaires et anticoagulants (à l’exception de l’aspirine faiblement dosée) dans les 24 heures avant la dose d’edoxaban jusqu’après le prélèvement du dernier échantillon pour la PK

    8. Les patients recevant un traitement par aspirine faiblement dosée (de 1 à 5 mg/kg/jour, jusqu’à maximum 100 mg/jour) avant une interruption de l’administration d’aspirine 24 heures avant la dose d’edoxaban et une reprise d’administration 24 heures après la dose d’edoxaban sont autorisés à participer à l’étude à la discrétion de l’investigateur s’il n’y a pas de risques pour le patient

    9. Les patients doivent accepter de s’abstenir de prendre tout inhibiteur/inducteur de CYP3A4 et de la P-gp dans les 14 jours qui précèdent la dose d’edoxaban jusqu’après le prélèvement du dernier échantillon pour la PK (voir Section 5.2)

    10. Les patients doivent accepter de s’abstenir de consommer et/ou les tuteurs légaux doivent accepter de s’abstenir de donner au patient du coca-cola, du thé, du café, du chocolat ou toute autre boisson ou aliment caféiné(e) dans les 48 heures qui précèdent l’administration de la dose jusque après la sortie (voir Section 5.3 pour connaître la liste complète)

    11. À l’exception des signes et symptômes propres à leur état pathologique, les patients doivent être en bonne santé, comme le définira l’absence de déviations cliniques significatives par rapport à la normale, en ce qui concerne les antécédents médicaux et chirurgicaux, l’examen physique, les signes vitaux et les analyses de laboratoire, comme demandé par l’investigateur et le promoteur, avant le recrutement

    12. Les patients doivent accepter de s’abstenir de consommer et/ou les tuteurs légaux doivent accepter de s’abstenir de donner au patient du millepertuis ainsi que des aliments/compléments alimentaires et des boissons contenant du pamplemousse, du jus de pamplemousse, et des oranges amères dans les 14 jours qui précèdent l’administration de la première dose jusqu’à la fin de l’étude (voir Section 5.3)
    E.4Principal exclusion criteria
    1. History (within the last 6 months) of abnormal coagulation tests during screening, as defined by local laboratory reference ranges, which are not explained by anticoagulation therapy
    2. Stroke where anticoagulant therapy is contraindicated
    3. Patients with stage 2 hypertension defined as blood pressure confirmed > 99th percentile + 5 mmHg
    4. Patients with renal function less than 50% of normal for age and size as determined by the National Kidney Disease Education Program version of the Schwartz formula8
    5. Actively bleeding or has a high risk of bleeding
    6. Has a currently active gastrointestinal ulceration or a known history of peptic ulcer or gastrointestinal bleeding (including hematemesis, melena, or rectal bleeding including bleeding from hemorrhoids) within the previous 6 months
    7. Has known diabetic retinopathy
    8. Has thrombocytopenia at screening (< 20 × 109/L)
    9. Has had other unrelated clinically significant illness within 4 weeks prior to Day 1, predose
    10. Planned invasive procedures during or within 24 hours of study drug administration
    11. Patient is receiving high-dose aspirin concurrently or within 2 weeks prior to dosing
    12. Use of P-gp or CYP 3A4 inhibitors or inducers within 14 days prior to the edoxaban dose and expected to continue through the study duration
    13. Patients with history of major bleeding and/or neurosurgery within 6 months of dosing
    14. Patients with history of major trauma or surgery within the last month
    15. Patients with known malabsorption disorders (e.g., cystic fibrosis or short bowel syndrome)
    16. Hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk or alanine transaminase (ALT) > 5 times the upper limit of normal (ULN) or total bilirubin > 2 times the ULN with direct bilirubin > 20% of the total
    17. Patient is currently enrolled in another investigational device or drug study, or is receiving other investigational agents. Patients must have completed the prior clinical study at least 30 days prior to dosing
    18. Patients of childbearing potential (post-menarche) who are sexually active and are not using approved contraception; who are pregnant (as based on test results); or are breastfeeding
    19. Females with history of abnormal menses, including history of menorrhagia (heavy menstrual bleeding), metrorrhagia, or polymenorrhea
    20. Patient has known sensitivity to the investigational product (IP) or any of its excipients
    21. Positive drug or alcohol screen (excluding cotinine) at screening for patients 12 years of age or older, for newborns and for patients who are being breastfed
    22. Patients who have received a transfusion or any blood products within 30 days prior to the first dose
    23. Any major bleeding during prior anticoagulant therapy
    24. Patients with any condition, that as judged by the Investigator, would place the patient at increased risk of harm if he/she participated in the study
    1. Antécédent (au cours des 6 derniers mois) de tests de coagulation anormaux lors de la sélection, tel que défini par les valeurs normales de laboratoire, qui ne s’expliquent pas par un traitement anticoagulant

    2. AVC, dans le cas duquel un traitement anticoagulant est contre-indiqué

    3. Patients présentant une hypertension de niveau 2 définie par une pression sanguine confirmée > 99e percentile + 5 mmHg

    4. Patients présentant des fonctions rénales inférieures à 50 % par rapport à la normale, compte tenu de l’âge et de la taille du patient, tel que déterminé par la version du National Kidney Disease Education Program (programme national à visée pédagogique concernant les maladies rénales) selon la formule de Schwartz8

    5. Saignement actif ou risque élevé d’hémorragie

    6. Avoir un ulcère gastro-intestinal actuellement actif ou un antécédent connu d’ulcère peptique ou de saignement gastro-intestinal (y compris hématémèse, méléna ou saignement rectal, incluant les saignements causés par des hémorroïdes) au cours des 6 mois précédents

    7. Avoir une rétinopathie diabétique connue

    8. Avoir une thrombocytopénie lors de la sélection (< 20 × 109/l)

    9. Avoir eu une autre maladie significative sans relation clinique dans les 4 semaines précédant le Jour 1, avant la dose

    10. Avoir des procédures invasives planifiées pendant ou dans les 24 heures suivant l’administration du médicament à l’étude

    11. Patient recevant de l’aspirine à forte dose simultanément ou dans les 2 semaines précédant l’administration de la dose

    12. Utilisation d’inhibiteurs ou d’inducteurs de la p-gp ou de CYP 3A4 dans les 14 jours qui précèdent la dose d’edoxaban et pendant toute la durée de l’étude

    13. Patients présentant des antécédents de saignement majeur et/ou neurochirurgie dans les 6 mois de l’administration de la dose

    14. Patients avec des antécédents de traumatisme ou de chirurgie majeur(e) au cours du dernier mois

    15. Patients présentant des troubles de malabsorption connus (par ex. fibrose cystique ou syndrome de l’intestin court)

    16. Présenter une maladie hépatique associée à une coagulopathie et conduisant à un risque hémorragique pertinent sur le plan clinique ou des taux d’alanine aminotransférase (ALAT) > 5 fois la limite supérieure de la normale (LSN) ou une bilirubine totale< 2 fois la LSN avec une bilirubine directe > 20 % du total

    17. Patient participant actuellement à une autre étude sur un médicament ou pour un dispositif expérimental, ou recevant d’autres agents expérimentaux. Les patients doivent avoir terminé l’étude clinique précédente au moins 30 jours avant de recevoir la dose


    18. Les patientes en âge de procréer (femmes menstruées) qui sont sexuellement actives mais qui n’utilisent pas de contraception approuvée, qui sont enceintes (selon les résultats du test de grossesse) ou qui allaitent

    19. Les femmes présentant des antécédents de menstruations anormales, y compris des antécédents de ménorragie (saignements menstruels importants), métrorragie ou polymenorrhée

    20. Patient présentant une sensibilité connue au produit expérimental ou à l’un de ses excipients

    21. Dépistage positif à la drogue ou à l’alcool (à l’exception de la cotinine) lors de la sélection pour les patients de 12 ans ou plus, pour les nouveau-nés et les patients nourris au sein

    22. Patients ayant reçu une transfusion ou tout produit sanguin dans les 30 jours qui précèdent la première dose

    23. Toute hémorragie majeure avant un traitement anticoagulant

    24. Patients dont l’état de santé, tel que jugé par l’investigateur, les exposerait à un risque accru s'ils participaient à l’étude
    E.5 End points
    E.5.1Primary end point(s)
    - The PK endpoints will include PK parameters such as apparent systemic clearance (CL/F) and apparent volume of distribution (V/F). If data permit, derived PK parameters such as AUC and metabolite/parent ratios for AUCs will also be estimated.
    Les paramètres pharmacocinétiques inclueront : clairance systémique apparente (CL/F), volume de distribution apparent (V/F) et aire sous la courbe concentration plasmatique-temps (AUC) pour l’edoxaban et les métabolites, et ratio métabolite/composé pour l’AUC.
    E.5.1.1Timepoint(s) of evaluation of this end point
    PK:
    - 0.25 to 1 hour postdose (1 sample)
    - 1.5 to 3 hours postdose (1 sample)
    - 3.5 to 6 hours postdose (1 sample)
    - 6.5 to 8 hours postdose (1 sample)
    - 8.5 to 14 hours postdose (1 sample)
    - 24 to 36 hours postdose (1 sample)
    - 48 to 54 hours postdose (1 sample)
    For subsequent age cohorts, emerging PK concentration-time data from completing patients will be analyzed on an ongoing basis and used to refine and optimize the PK blood sampling scheme (i.e., both the number of samples and the sampling windows).
    PK:
    - 15 minutes à 1 heure post-dose (1 échantillon)
    - 1h30 à 3 heures post-dose (1 échantillon)
    - 3h30 à 6 heures post-dose (1 échantillon)
    - 6h30 à 8 heures post-dose (1 échantillon)
    - 8h30 à 14 heures post-dose (1 échantillon)
    - 24 à 36 heures post-dose (1 échantillon)
    - 48 à 54 heures post-dose (1 échantillon)
    Pour les autres cohortes,les données de PK des patients ayant déjà réalisés l'étude seront analysées au fur et à mesure afin de re-définir et d'optimiser le schéma de prévelèvement de sang (comme le nombre d'échantillon et les fenêtres de prélèvement).
    E.5.2Secondary end point(s)
    - The PD endpoints will include observed, change-from-baseline, and percent-change-from-baseline PT, aPTT, and anti-FXa.
    - Safety assessments will include: AEs, physical examination findings, vital signs, standard hematology, clinical chemistry, coagulation, and urinalysis laboratory tests. Note, urinalysis will be performed with plastic bags with a sticky strip from neonates and infants with diapers.
    - Palatability of the liquid formulation will be assessed using visual analog scale (VAS) scores.
    Pharmacodynamique :
    Observés, changements par rapport à la référence et pourcentage de changement par rapport à la référence des biomarqueurs TP, TTPa et du facteur anti-Xa.

    Sécurité d'emploi :
    Évaluations de la sécurité d’emploi : effets indésirables, résultats d’examen clinique, signes vitaux, analyses laboratoires cliniques, évaluations de la coagulation et analyses d’urine.

    Autre :
    La palatabilité de la formule liquide sera évaluée à l’aide d’une échelle visuelle analogique (VAS).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Coagulation:
    - Predose (1 sample)
    - 0.25 to 1 hour postdose (1 sample)
    - 1.5 to 3 hours postdose (1 sample)
    - 3.5 to 6 hours postdose (1 sample)
    - 6.5 to 8 hours postdose (1 sample)
    - 24 to 36 hours postdose (1 sample)
    All other secondary endpoints - throughout the study
    Coagulation:
    - Predose (1 échantillon)
    - 15 minutes à 1 heure post-dose (1 échantillon)
    - 1h30 à 3 heures post-dose (1 échantillon)
    - 3h30 à 6 heures post-dose (1 échantillon)
    - 6h30 à 8 heures post-dose (1 échantillon)
    - 24 à 36 heures post-dose (1 échantillon)
    Tous les autres critères secondaires - tout au long de l'étude
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Metabolite exposure, palatability
    Exposition aux métabolites, palatabilité
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    PK, PD safety study
    Pharmacocinétique, Pharmacodynamie, Sécurité d'emploi
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Dose unique
    Single-dose
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA12
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Egypt
    Italy
    Jordan
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Dernière visite d'étude du dernier patient inclus
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 48
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 12
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 24
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 12
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Children <6 will be enrolled solely via parental authorization. Children 6 - 17 will be enrolled via assent and parental consent.
    Les enfants en dessous de 6 ans seront inclus sur la base de l'autorisation donnée par leurs parents. Les enfants âgés de 6 à 17 ans seront inclus sur la base de leur assentiment et de l'autorisation de leurs parents.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state4
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 48
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will continue normal treatment.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-09-16
    N.Ethics Committee Opinion of the trial application
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion
    P. End of Trial
    P.End of Trial Status
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA